



# Transform MASH & Liver pathology into quantitative insights for next generation drug development & clinical trials

Accelerating biomarker discovery in MASLD and liver diseases with cellular-level AI-driven fibrosis grading and microarchitecture insights.

## Experience AI-powered pathology


**Liver Explore™ - Visualize Pathology with Pixel-Level Precision**



**Comprehensive data directly enables statistical analysis to test hypotheses**

FEATURES OF FIBROGENESIS REDUCTION						FEATURES OF INFLAMMATORY RESPONSE			
Area Prop Periportal Fibrosis to Total Tissue	Area Prop Periportal Fibrosis to Total Tissue	Area Prop of Incomplete Septal Fibrosis in Zone 3	Density of Fibroblasts in Advanced Fibrosis regions	Count Prop Lymphocytes over all Immune Cells in Inflammation	Area Prop of Inflammation Reduction to All Septal Fibrosis	Count Prop Lymphocytes over all Immune Cells in Inflammation	Area Prop Lobular Inflammation in Zone 2	Density of Immune Cells in Tissue	Density of Immune Cells in Tissue
0.00406	0.03156	2095.108	0.335917	0.01242	1885.608	0.335917	0.01242	1885.608	1885.608
Slide ID	Area Prop Periportal Fibrosis to Total Tissue	Area Prop of Incomplete Septal Fibrosis in Zone 3	Density of Fibroblasts in Advanced Fibrosis regions	Count Prop Lymphocytes over all Immune Cells in Inflammation	Area Prop of Inflammation Reduction to All Septal Fibrosis	Density of Immune Cells in Tissue	Density of Immune Cells in Tissue	Standard Deviation of Mean Area Prop of Inflammation	Standard Deviation of Mean Area Prop of Inflammation
542763	0.00406	0.03156	2095.108	0.335917	0.01242	1885.608	0.335917	0.01242	1885.608
542766	0.020959	0.01237	1757.021	0.318859	0.029914	2871.111	0.318859	0.029914	2871.111
542767	0.008419	0.001423	1683.409	0.300402	0.007732	2920.300	0.300402	0.007732	2920.300
542768	0.009302	0.000023	912.9354	0.340100	0.001242	2727.716	0.340100	0.001242	2727.716
542769	0.000000	0.000000	0.000000	0.340100	0.000000	0.000000	0.340100	0.000000	0.000000

**Support throughout various stages of the development lifecycle and pipeline**  
Integrating unique solutions to your most pressing clinical challenges



# End-to-end pathology workflows customized to your trial for compliant and efficient AI deployment

### AIM MASH<sup>+</sup> AI Assist

Pathologist assist tool for clinical trial histology endpoint assessment to **reduce impact of reader variability** and **capture true drug effect**.

### AIM MASH<sup>+</sup>

Ordinal and continuous MASH CRN scores to drive more **nuanced / deeper understanding** of changes within ordinal bins.

### LiverExplore

AI-powered solution delivering histopathology features of tissue microarchitecture to uncover **insights into drug MOA and beyond**.

DATA INPUT

#### AI-Assist Report

- Pathologist AI-Assisted ordinal MASH CRN scores
- AI-alone ordinal MASH CRN scores

#### Feature Reports



- AI-alone ordinal MASH CRN scores
- AI-derived continuous MASH CRN scores
- Artifact model QC features

#### Feature Reports

- **>1000 quantitative features:** tissue, cell & nuclear features, lobular zones, & fibrosis subtypes
- Artifact model QC features

H&E Report				
	AIM-MASH	Pathologist		Final
Steatosis	2	2	✓	2
Ballooning	1	2	✓	1
Lob. Inflam.	1	3	✗	3

MT Report				
	AIM-MASH	Pathologist		Final
Fibrosis	4	4	✓	4



Learn more at [www.pathai.com](http://www.pathai.com)

Contact us at [bd@pathai.com](mailto:bd@pathai.com)

Demo the platforms: [info.pathai.com/pathai-demo-the-platforms](http://info.pathai.com/pathai-demo-the-platforms)

Liver Explore™ and AIM-MASH Products are for research use only. Not for use in diagnostic procedures.

© 2024 PathAI, Inc. | PathAI and its logo are registered trademarks of PathAI. All rights reserved.

[www.pathai.com](http://www.pathai.com)

1325 Boylston Street Suite 10000 Boston, MA 02215